Lilly-Verve deal sends gene editing stocks higher
Source: SeekingAlpha
2025-06-17 10:29:37 ET
More on Eli Lilly, Verve Therapeutics
- Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)
- Eli Lilly and Company (LLY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
- Eli Lilly: If You Don't Buy On Weight Loss Promise Now, You Probably Never Will
- Biggest stock movers Tuesday: Solar stocks, VERV, and more
- 4 stocks to watch on Tuesday: JBL, TMUS, LLY and YUM
Read the full article on Seeking Alpha
For further details see:
Lilly-Verve deal sends gene editing stocks higher
First Trust Heitman Global Prime Real Estate ETF
NASDAQ: PRME
PRME Trading
0.41% G/L:
$3.68 Last:
969,683 Volume:
$3.59 Open:
PRME Latest News
March 03, 2026 08:00:00 am
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
PRME Stock Data
$629,079,643
97,403,551
13.07%
59
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
